Gene Therapy for Hemophilia

Human Gene Therapy

Volumn 27, Issue 4, 2016, Pages 305-308

  Nienhuis, Arthur W ^a   Nathwani, Amit C ^b   Davidoff, Andrew M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 9; NEUTRALIZING ANTIBODY;

ARTICLE; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HEMATOPOIETIC CELL; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNE RESPONSE; MOUSE; MUSCLE BIOPSY; NONHUMAN; PROMOTER REGION; SEROTYPE; TRANSIENT TRANSFECTION; ANIMAL; CLINICAL TRIAL (TOPIC); DEPENDOPARVOVIRUS; METABOLISM;

ANIMALS; CLINICAL TRIALS AS TOPIC; DEPENDOVIRUS; GENETIC THERAPY; HEMOPHILIA A; HEMOPHILIA B; HUMANS;

EID: 84964575993     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2016.018     Document Type: Article

References (27)

1. Stamatoyannapoulos G, Nienhuis AW. Cellular and Molecular Regulation of Hemoglobin Switching. (Grune & Stratton, Inc., New York, NY). 1979.
2. Nathwani AC, Nienhuis AW, Davidoff AM. Our journey to successful gene therapy for hemophilia B. Hum Gene Ther 2014;25:923-926.
3. Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007;110:815-825.
4. Nathwani AC, Hanawa H, Vandergriff J, et al. Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38-subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wildtype AAV. Gene Ther 2000;7:183-195.
5. Davidoff AM, Gray JT, Ng CYC, et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with a serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther 2005;11:875-888.
6. Gao G-P, Alvira MR, Wang L, et al. Novel adenoassociated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Aacad Sci USA 2002;99:11854-11859.
7. Samulski RJ, Scrivastava A, Berns KI, et al. Rescue of adeno-associated virus from recombinant plasmids: Gene correction within the terminal repeats of AAV. Cell 1983;33:135-143.
8. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000;24:257-261.
9. Manno CS, Chew AJ, Hutchison S, et al. AAVmediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003;101:2963-2972.
10. Buchlis G, Podsakoff GM, Radu A, et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 2012;119:3038-3041.
11. Manno C, Pierce G, Arruda V, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-347.
12. Mingozzi F, Maus V, Hui D, et al. CD8+ T-cells responses to adeno-associated virus capsid in humans. Nat Med 2007;13:419-422.
13. Pien GC, Basner-Tschakarjan E, Hui DJ, et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest 2009;119:1688-1695.
14. Hurlbut GD, Ziegler RJ, Nietupski JB, et al. Preexisting immunity and low expression in primates highlight translational challenges for liverdirected AAV8-mediated gene therapy. Mol Ther 2010;18:1983-1994.
15. McIntosh JH, Cochrane M, Cobbold S, et al. Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAVmediated gene transfer with a non-depleting CD4 antibody and cyclosporine. Gene Ther 2012; 19:78-85.
16. Jiang H, Couto LB, Patarroyo-White S, et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 2006;108:3321-3328.
17. Thomas CE, Storm TA, Huang Z, et al. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adenoassociated virus vectors. J Virol 2004;78:3110-3122.
18. McCarty DM, Fu H, Monahan PE, et al. Adenoassociated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003;10:2112-2118.
19. Wang Z, Ma H-I, Li J, et al. Rapid and highly efficient transduction by double-stranded adenoassociated virus vectors in vitro and in vivo. Gene Ther 2003;10:2105-2111.
20. Nathwani AC, Gray JT, Ng CYC, et al. Selfcomplementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 2006;107:2653-2661.
21. Nathwani AC, Gray JT, McIntosh J, et al. Safe and efficient transduction of the liver and peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 2007; 109:1414-1421.
22. Nathwani AC, Reiss UM, Tuddenham EGD, et al. Long-term safety and efficacy of Factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371:1994-2004.
23. Nathwani AC, Tuddenham EG, Rangaraian S, et al. Adeno-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365:2357-2365.
24. Crudele JM, Finn JD, Siner JI, et al. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood 2015;125: 1553-1561.
25. Nair N, Rincon MY, Evens H, et al. Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy. Blood 2014;123:3195-3199.
26. Monahan PE, Sun J, Gui T, et al. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: Preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther 2015;26:69-81.
27. McIntosh J, Lenting PJ, Rosales C, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 2013; 121:3335-3344.